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Abstract
Background: Blastocystis is a group of cosmopolitan gastrointestinal parasite of humans and a wide variety of
animals. These anaerobic protozoans include more than 17 specific small-subunit ribosomal RNA subtypes, of which
nine are found in humans with a variable geographical distribution. Until now, no study has described the Blastocystis
subtypes present in Saudi Arabia.
Methods: In total, 1,262 faecal samples were collected from patients with gastrointestinal complaints and asymptomatic
individuals visiting two major hospitals. All samples were analysed by F1/R1 diagnostic PCR, microscopy and culture
methods. The subtypes of Blastocystis sp. isolates were determined by the sequenced-tagged site (STS)-based method.
Results: One-hundred-thirty-three positive cases were detected by F1/R1 diagnostic PCR, of which 122 were also
positive by the culture method and 83 by direct microscopy. The sensitivities of direct microscopy and the culture
method were 62% and 92%, respectively. Subtype (ST3) was the most prevalent (80.5%), followed by ST1 (14.5%) and
ST2 (5%). ST4, ST5, ST6 and ST7 were not detected in this study. ST3 infections were significantly predominant (P < 0.05)
among symptomatic patients.
Conclusions: To our knowledge, this study provides the first run-through information on Blastocystis sp.
epidemiology in Makkah city, revealing a rather moderate prevalence of 10.5% and the presence of three
subtypes, ST1, ST2, and ST3. ST3 was the most predominant, particularly among symptomatic patients.
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Background
Blastocystis is a group of cosmopolitan gastrointestinal
anaerobic protozoan parasites. The group is known to in-
fect humans and a wide variety of animal hosts, including
mammals, birds, amphibians, and reptiles [1]. The life-
cycle comprises numerous ‘forms’, including granular cysts
and multivacuolar, avacuolar, vacuolar, and amoeboid
structures. The mode of infection has not been completely
understood until now, but involves faecal-oral ingestion of
a cyst, with animal handlers showing significantly high
rates of infection [2, 3]. Blastocystis has a worldwide
distribution with a marked prevalence in many countries.
According to most epidemiological studies, nearly all
countries of the world have been classified into well-
developed, with a moderate prevalence (10-15%), or
under-developed, with a high prevalence (55–70%), attrib-
uted to the levels of hygiene and the presence or absence
of contact with animals and/or contaminated water and
food [4, 5].
Blastocystis may exist in the gut for years; however, the
recognition of a high prevalence of Blastocystis in healthy
populations using sensitive molecular diagnostic tools has
led to a standard shift in clinical Blastocystis research.
Studies of the gut microbiota in individuals with and with-
out Blastocystis can provide important information to help
determine the role of Blastocystis in human health and
disease [6]. Additionally, the Blastocystis parasite appears
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to be more common in healthy individuals than in pa-
tients with inflammatory bowel disease and is associated
with certain gut microbiota and health indicators. Al-
though the parasite may elicit disease under certain condi-
tions, the focus on Blastocystis may be shifting from a
clinical to a public health viewpoint [7]. SSU rRNA-based
phylogeny and host origins do not associate with each
other for the classification of different Blastocystis isolates
that are derived from humans to insects. The Blastocystis
sp. subtype (ST) classification is applied for Blastocystis
isolates from homoeothermic animals because their origin
is from humans, and they are classified into nine genetic-
ally different STs. However, the situation in poikilothermic
animals, such as reptiles and amphibians, suggests difficul-
ties; therefore, determining the complete sequence of SSU
rDNA is essential to establish novel ST in the phylogen-
etic analysis [8].
In Blastocystis sp. infection, the symptoms are mostly
nonspecific and include weight loss, nausea, vomiting,
flatulence, abdominal pain, and diarrhoea [9, 10]. How-
ever, the pathogenicity of this parasite is still argumenta-
tive and non-conclusive; Blastocystis sp. infections have
been reported in several countries in many asymptom-
atic and apparently healthy individuals as well as in
symptomatic cases without any obvious causal organ-
isms [2]. Several studies have deduced that only a few
subtypes of Blastocystis sp. can cause symptoms. It was
concluded that the proteases of Blastocystis sp. subtype
3 (ST3) were responsible for protein degradation with
host immune evasion and are an important virulence
factor [11, 12]. Another study correlated Blastocystis sp.
subtype 3 infections with idiopathic urticaria [12].
In last few years, several molecular tools have been
used to classify the Blastocystis sp. subtypes isolated
from humans and animals in different regions worldwide.
These techniques include random amplified polymorphic
DNA (RAPD) using four different arbitrary polymerase
chain reaction (PCR) primers [13] and PCR assays followed
by restriction fragment length polymorphism (RFLP) to
study the sequence variation in the small-subunit riboso-
mal RNA genes of isolates [14]. More recently, new PCR-
based methods have been developed for subtype classifica-
tion using known sequenced-tagged site (STS) primer sets
[15] in combination with single-strand conformational
polymorphism (SSCP) analysis [1] or post-PCR pyrose-
quencing techniques based on the detection of subtype-
specific nucleotide polymorphism in the SSU rRNA gene
[16, 17], fingerprinting with AP-PCR [18], and multilocus
sequence typing [19]. The latest epidemiological studies
have shown the great diversity of Blastocystis sp. subtypes;
ten subtypes (ST1 to ST10) have been found according to
SSU rRNA gene sequences [20]. Seven other subtypes
(ST11–ST17) have been identified in isolates from live-
stock and zoo animals [21]. Among all identified subtypes,
only ST1 to ST9 are considered to be human Blastocystis
sp. subtypes [10, 22]. Some authors recommend a
standardization of Blastocystis terminology to simplify
statements and show the relationships of the research re-
sults. This primarily depends on the already published data
on small-subunit ribosomal RNA gene analyses and sug-
gests that all mammalian and avian isolates should be
nominated as Blastocystis sp. [23]. Using Blastocystis gen-
etic markers, the barcode region is the best region to use
in publicly available sequence databases at GenBank, while
the STS primers represent a suitable approach in situations
where sequencing is not an option, and the disadvantages
of using STS primers are that some subtypes will go un-
detected, includes ST8 and ST9 and also the majority of
ST4 strains [24].
To our knowledge, no previous study has explored the
prevalence and subtype distribution of Blastocystis sp. in
Saudi Arabia. The aim of the present study was to ex-
plore the Blastocystis sp. relative prevalence and sub-
types present in one of the major cities in Saudi Arabia.
This survey was performed on faecal samples collected
from symptomatic and asymptomatic individuals who
visited, over a 10-month period, two major hospitals of
Makkah city, Saudi Arabia.
Methods
Sample collection
This study was carried out from March 2014 to January
2015 at two major health care centres of Makkah city, King
Abdellah medical city and Al-Noor Specialist Hospital. Of
all faecal specimens received during this period by Parasit-
ology Laboratory units, in both hospitals, 1,262 specimens
were included in this investigation. Approximately 50% of
the collected samples were from patients with gastro-
intestinal complaints, including severe abdominal pain
and diarrhoea, and the other 50% were from appar-
ently healthy individuals who underwent a regular
check-up or mandatory health check.
Microscopic examination and in vitro culture
The referred faecal specimens are routinely examined by
microscopy for parasitic infections using the direct
smear method with saline and iodine. Samples from sus-
pected patients, if negative by direct microscopy, are fur-
ther examined after trichrome permanent staining and
according to the formalin ethyl acetate concentration.
For this study, each collected sample was split into two
parts; one part was kept at -20 °C, and the other part
was inoculated in culture media and transferred to the
medical parasitology laboratory of the Faculty of Medi-
cine at Umm Al Qura University for sub-culturing and
molecular analysis. The culture medium consisted of
Dulbecco's modified Eagle medium (DMEM) (Gibco,
Thermo Fisher Scientific, MA, USA) containing 12 mg/
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ml ampicillin and 4 mg/ml streptomycin supplemented
with 20% inactivated horse serum (Gibco) sterilized by
filtration [25]. The samples were cultured in 11 ×
100 mm sterile screw-capped tubes containing 3 ml of
media and were incubated at 37 °C in an anaerobic gas
pack (BD gas pack-Becton, Dickinson, USA). A drop of
culture was examined after 72 h by direct microscopy.
DNA extraction
Genomic DNA was extracted directly from stool samples
using the ZR faecal DNA miniprep kit (Zymo Research,
Tustin, CA, USA) and from cell pellets of positive cultures
using the QIAmp DNA extraction kit (QIAmp, QIAGEN,
Inc., Hilden, Germany), according to manufacturers’ pro-
tocols. The concentration and purity of isolated DNA
were measured by a spectrophotometer (SpectraDrop;
SpectroMax, Life Technology, Carlsbad City, CA, USA).
F1/R1 diagnostic PCR
Diagnostic PCR was applied to genomic DNA extracted
from stool specimens using the F1 (5'-GGA GGT AGT
GAC AAT AAA TC-3') and R1 (5'-CGT TCA TGA TGA
ACA ATT AC-3') primers [26]. Briefly, 2 μl of genomic
DNA was used in PCR reactions of a 25 μl final volume
using the AmpliTaq Gold 360 master mix (Applied Bio-
systems, CA, USA). The PCR conditions consisted of
one cycle of initial denaturation at 94 °C for 4 min,
followed by 35 cycles of denaturation at 94 °C for 30 s,
annealing at 54 °C for 30 s, extension at 72 °C for 30 s,
and a final elongation cycle for 5 min at 72 °C.
Blastocystis sp. subtyping using Sequence-Tagged Site
(STS) primers
PCR reactions were carried out using sequence-tagged
site primer sets derived from the RAPD product se-
quence to identify the subtypes as follows: ST1 variant
(SB82: 5'-TCT TGC TTC ATC GGA GTC / CCT TCT
CGC AGT TCT TTA TC-3'), ST1 (SB83: 5'-GAA GGA
CTC TCT GAC GAT GA / GTC CAA ATG AAA GGC
AGC-3'), ST7 (SB155: 5'-ATC AGC CTA CAA TCT
CCT C / ATC GCC ACT TCT CCA AT-3'), ST3 by
multiplex PCR including (SB227: 5'-AGG ATT TGG
TGT TTG GAG A / TTA GAA GTG AAG GAG ATG
GAA G-3', SB228: 5'-GAC TCC AGA AAC TCG CAG
AC / TCT TGT TTC CCC AGT TAT CC-3' and SB229:
5'-CAC TGT GTC GTC ATT GTT TTG / AGG GCT
GCA TAA TAG AGT GG-3'), ST6 (SB332: 5'-GCA TCC
AGA CTA CTA TCA ACA TT / CCA TTT TCA GAC
AAC CAC TTA-3'), ST5 (SB336: 5'-GTG GGT AGA
GGA AGG AAA ACA / AGA ACA AGT CGA TGA
AGT GAG AT-3'), ST4 (SB337: 5'-GTC TTT CCC TGT
CTA TTC TTG CA / AAT TCG GTC TGC TTC TTC
TG-3'), and ST2 (SB340: 5'-TGT TCT TGT GTC TTC
TCA GCT C / TTC TTT CAC ACT CCC GTC AT-3')
[15]. Two microlitres of DNA extract were used in PCR
reactions of a 25 μl final volume using the AmpliTaq
Gold 360 master mix (Applied Biosystems, Carlsbad
City, CA, USA). The PCR conditions consisted of one
cycle of initial denaturation at 94 °C for 5 min, followed
by 40 cycles that included denaturation at 94 °C for 30 s,
annealing at 57 °C for 30 s, extension at 72 °C for 1 min,
and a final elongation cycle for 5 min at 72 °C. All PCR
amplifications were carried out in duplicate for each
sample and each primer set. The PCR products were
separated in 1.5% agarose gels and were photographed.
Statistical analysis
The data were analysed using the Chi-square test to
compare the frequency of the Blastocystis sp. subtypes
from symptomatic and asymptomatic individuals. A
P-value < 0.05 was statistically significant. Statistical ana-
lysis was performed using SPSS version 21.
Results
Relative prevalence of Blastocystis sp. based on microscopy
and in vitro culture
Of 1,262 examined faecal samples, 133 specimens were
found to be positive for Blastocystis by the F1/R1 diag-
nostic PCR technique used in this study. Among positive
cases, 85 (64%) were patients with gastrointestinal symp-
toms and 48 (36%) were asymptomatic individuals. The
general symptoms consisted of abdominal pain in ap-
proximately 76%, diarrhoea in approximately 27% and
other gastrointestinal complaints in approximately 16%
of the symptomatic patients. All 133 positive cases were
detected by F1/R1 diagnostic PCR, of which 122 were
also positive by the culture method and 83 by direct mi-
croscopy. The sensitivities of direct microscopy and the
culture methods compared with that of F1/R1 PCR and
are shown in Table 1.
STS subtyping analysis of Blastocystis sp. isolates
Three Blastocystis sp. subtypes (ST1, ST2 and ST3) were
detected by STS primer-based PCR analysis of positive
samples. ST3 was the most prevalent (80.5%), followed
by ST1 (14.5%) and ST2 (5%). ST4, ST5, ST6 and ST7
were not detected in this study. ST3 infections were sig-
nificantly predominant (χ2 = 6.54, df = 2, P = 0.038)
among symptomatic patients (Fig. 1). The Blastocystis
sp. subtype distribution did not show a predisposition in
relation to the age or gender of infected individuals.
Discussion
In this study, the relative prevalence of Blastocystis sp.
infection among individuals with or without gastrointes-
tinal symptoms who visited two major hospitals in
Makkah city was determined to be 10.5%. Since the
prevalence data are usually derived from general surveys
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of intestinal parasites using the formol acetate concen-
tration technique with microscopic examination, such
numbers should be interpreted with extreme caution be-
cause the sensitivities of this method are lower than
those of nucleic acid-based methods, including conven-
tional and real-time PCR [7]. Epidemiological studies in
several countries with different sanitation standards re-
vealed wide ranges of Blastocystis sp. prevalence: 0.54%
in Turkey [27], 2.5% in Japan [15], 3.3% in Singapore
[28], 19% in Lebanon [29], 22.1% in Libya [30], 33.3% in
Egypt [31], 40.7% in the Philippines [32] and 46.9% in
Venezuela [33]. Thus, the prevalence found herein is
relatively moderate compared with the worldwide gen-
eral infection situation.
Numerous conflicting reports on the pathogenic cap-
ability of Blastocystis sp. infection have been published,
and it is still under debate whether Blastocystis sp. is a
pathogenic or a commensal life form [2]. In our study,
Blastocystis infections were detected both in patients
with patent gastrointestinal symptoms (85 cases) and in
apparently healthy individuals (48) who underwent
mandatory health check-ups. Additionally, 78.5% of
symptomatic patients and 21.5% of asymptomatic indi-
viduals with PCR-positive infections were positive by mi-
croscopy; accordingly, it has been reported that the
Blastocystis cell density is usually significantly higher in
symptomatic patients [34]. Comparative studies of human
immunity against Blastocystis infection have revealed a
significant difference in antibody responses between
symptomatic and asymptomatic individuals [35, 36]. How-
ever, antigenic heterogeneity has been detected between
Blastocystis sp. isolated from symptomatic patients and
asymptomatic individuals in axenic culture; however, these
studies did not explore any possible correlations between
this heterogeneity and genetic subtypes [37].
Nine subtypes of Blastocystis sp. (ST1 to ST9) were
identified in humans [10]. To our knowledge, this is the
first report exploring the subtypes of Blastocystis in
Makkah city, Saudi Arabia. Using sequence-tagged site
(STS) primer-based PCR, we found three Blastocystis sp.
subtypes (ST1, ST2 and ST3) among the 133 positive
cases. The high predominance of ST3 (80.5%) in our study
population agrees with different reports in the literature;
ST3 was found to be the most dominant subtype, varying
from 41% to 92%, in a comparative study between Japan,
Bangladesh, Pakistan and Germany [15] and at 78%,
75.9%, 54.5%, 53.5% and 33.3% in Singapore, Turkey,
Egypt, France and Lebanon, respectively [28, 29, 38–40].
Table 1 Sensitivity of F1/R1 PCR, direct microscopy, and the
culture method for the diagnosis of Blastocystis sp. infections in











Direct microscopy 65 18 83 62%
In vitro culture 79 43 122 92%
F1/R1 PCR 85 48 133 100%
Fig. 1 Subtype distribution of Blastocystis sp. among gastrointestinal patients and asymptomatic individuals. Subtype 3 was 69% in symptomatic
patients and 31% in asymptomatic individuals (χ2 = 6.54, df = 2, P < 0.05)
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However, the ST1 (50%) subtype was found to be more
predominant than ST3 (39.5%) in the Libyan population
[41], as confirmed by a more recent study reporting the
predominance of ST1 (51.1%) over ST3 (17.8%) in
Libya [30]. Although ST2 is commonly reported to be
the second most prevalent subtype [42–45], in our
study, only 5% of cases carried the ST2 subtype, while
14.5% carried ST1.
Subtypes ST4, ST5, ST6 and ST7, as reported in previ-
ous studies [39, 46, 47], were not detected in our investi-
gation. ST4 was remarkably common in Danish patients
with acute diarrhoea [48], symptomatic patients in Spain
[43], and rural communities in Nepal [49]. ST6 and ST7
were reported in the Middle East both in irritable bowel
syndrome patients and healthy persons [39, 47]. How-
ever, ST5 was mostly reported in animals and humans
living near to farms [16, 50].
In many previous studies, no association was re-
ported between the specific subtype of Blastocystis sp.
and explicit gastrointestinal symptoms [40, 46, 51].
However, other studies reported a specific association
between subtypes of the parasite and apparent symp-
toms: it was demonstrated that Blastocystis cysteine
proteinase can degrade human IgA [52]. Additionally,
patients with chronic gastrointestinal illness with re-
ported antibiotic failure for over four years were diag-
nosed with ST3 and ST1 infections [53]. More
recently, irritable bowel syndrome in several Mexican
patients was associated with Blastocystis sp. ST1 and
ST3 infections [54]. Consistently, ST3 infections were
significantly predominant among symptomatic pa-
tients (69%) in our study. Blastocystis sp. ST2 infection
was linked to gastrointestinal illness and chronic urti-
caria [55].
In our findings, this subtype did not show an apparent
predominance in distribution between symptomatic and
asymptomatic infected individuals. However, it appears
that the Blastocystis sp. infection clinical outcome is
multifactorial, complicating the evaluation of its patho-
genicity, even during case-controlled studies [5].
Conclusions
The outcome of this study provides the first run-
through information on Blastocystis sp. epidemiology in
Makkah city, revealing a relatively moderate prevalence
(10.5%), as well as the presence of three subtypes: ST3,
the most predominant particularly among symptomatic
patients; ST1; and ST2. Further screenings are needed to
clarify the epidemiology of this gastrointestinal parasite
in local and emigrant populations of the entire country.
Likewise, the present study underlines the advantage of
STS-PCR as a significant technique for Blastocystis sp.
subtyping in epidemiological studies.
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